Humacyte, Inc. $HUMA Stake Lowered by CenterBook Partners LP

CenterBook Partners LP decreased its stake in Humacyte, Inc. (NASDAQ:HUMA) by 91.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 283,627 shares of the company’s stock after selling 3,146,628 shares during the period. CenterBook Partners LP’s holdings in Humacyte were worth $494,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in HUMA. Prudential Financial Inc. bought a new position in Humacyte during the 2nd quarter worth $28,000. Financial Advisors Network Inc. bought a new stake in Humacyte in the second quarter valued at $28,000. Vanguard Personalized Indexing Management LLC acquired a new position in shares of Humacyte during the second quarter valued at $30,000. Valeo Financial Advisors LLC bought a new position in shares of Humacyte during the second quarter worth about $32,000. Finally, Truist Financial Corp bought a new position in shares of Humacyte during the third quarter worth about $28,000. Institutional investors and hedge funds own 44.71% of the company’s stock.

Wall Street Analyst Weigh In

HUMA has been the subject of a number of analyst reports. D. Boral Capital reissued a “buy” rating and set a $25.00 target price on shares of Humacyte in a research note on Thursday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Humacyte in a research report on Monday, December 29th. HC Wainwright restated a “buy” rating and issued a $3.00 target price on shares of Humacyte in a research report on Monday, December 1st. Benchmark reduced their price target on Humacyte from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, January 21st. Finally, BTIG Research reissued a “buy” rating and issued a $6.00 price target on shares of Humacyte in a research note on Monday, February 9th. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $8.14.

Humacyte Trading Down 1.7%

Shares of Humacyte stock opened at $1.13 on Friday. The business has a fifty day simple moving average of $1.06 and a 200-day simple moving average of $1.39. Humacyte, Inc. has a fifty-two week low of $0.88 and a fifty-two week high of $3.94. The firm has a market cap of $211.62 million, a price-to-earnings ratio of -4.91 and a beta of 1.93. The company has a quick ratio of 0.90, a current ratio of 1.62 and a debt-to-equity ratio of 2.97.

Humacyte Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.